Haematomas After Percutaneus Vacuum-Assisted Breast Biopsy

Hertl, Kristijana; Marolt-Mušič, Maja; Kocijančič, Igor; Prevodnik-Kloboves, V; Žgajnar, Janez

doi:10.1055/s-2007-963724

Cited by 9 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher hematoma rates in our study compared to those of the literature may originate from the goal of excising all lesions or early periods of the follow-up ultrasound. In a study, the rate of hematoma detected by USG has been given as 94% in the 1 st week and 55% in the 3 rd week following stereotactic VABB (16). Hematomas were resorbed during follow-up and the rates of hematoma decreased in follow-up in our study, too.…”

Section: Discussionsupporting

confidence: 54%

Both a biopsy method and a therapeutic procedure in BI-RADS 4A and 4B lesions: Ultrasound-guided vacuumassisted breast biopsy

et al. 2020

View full text Add to dashboard Cite

Objective: This study aimed to evaluate outcomes, complications, and follow-up results of ultrasound-guided vacuum-assisted breast biopsy (UG-VABB) in BI-RADS 4 A and B lesions. Material and Methods: Between Agust 2014 to January 2018, fifty BI-RADS 4A and BI-RADS 4B lesions of 41 patients biopsied with 10G vacuum needle by a single radiologist were retrospectively evaluated. Results: All patients were females and mean age of the 41 patients was 50.12 ± 8.63. Of all lesions, 84% was benign, 6% was ADH, 4% was in-situ cancer, and 6% was diagnosed as malign. Follow-up duration after VABB was 0-51 months and mean was 20.92 months. Complications were as vasovagalinduced seizure in 3 patients (7.3%) and intramammary hematoma in 16 patients (39%). Hematoma was diagnosed in 3 patients (7.3%) at the 6 th month follow-up and it was resolved in all patients at the 12 th month follow-up. Higher breast density resulted in higher hematoma rates. There was no relationship between lesion BI-RADS subgroups, lesion size or sample number and hematoma development. During the follow-up, residue lesion in 1 (2.4%) patient and scar tissue in 2 (4.9%) patients was detected. Conclusion: US-guided VABB, with low complication rates and low scar development, is also a therapeutic excision method without remaining residue, which should be primarily preferred in smaller than 2 cm BI-RADS 4A and 4B lesions whose malignancy rates are relatively low. Hematoma, which is the most frequent complication, resorbed entirely in the 12 th month in all patients.

show abstract

Section: Discussionsupporting

confidence: 54%

Both a biopsy method and a therapeutic procedure in BI-RADS 4A and 4B lesions: Ultrasound-guided vacuumassisted breast biopsy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Emirates (1), Britain (1), Switzerland (1), Israel (1), New Zealand (1), and Canada (1). VABB was performed using US (24) and mammography (12) location modes. In this study, it mainly used five techniques: VABB of 8-(14), 9-(1), 10-(1), 11-(24), or 14-(5) gauge Mammotome probes.…”

Section: Key Messagesmentioning

confidence: 99%

Feasibility and safety of image‐guided vacuum‐assisted breast biopsy: A PRISMA‐compliant systematic review and meta‐analysis of 20 000 population from 36 longitudinal studies

Fang

Liu

Luo

et al. 2019

International Wound Journal

View full text Add to dashboard Cite

Breast cancer is a serious disease in women. We estimated the global technical success rate and complication rates of percutaneous vacuum‐assisted breast biopsy (VABB). PubMed, Embase, Web of Science, and Scopus databases were retrieved up to July 2018 to find studies in which technical success rate and complication rates of VABB were available. Pooled rates were calculated according to location mode (ultrasonography [US] or mammography) and needle type (8‐ or 11‐gauge Mammotome probes). Of the 36 articles with 20 868 cases, we found the pooled technical success rate 0.9999(0.9997, 1.0000) (I2 = 17.1%, P = .187) and low complication risks including haematoma 0.1092(0.0748, 0.1437) (I2 = 98.3%, P < .001), pain 0.0738(0.0334, 0.1141) (I2 = 95.9%, P < .001), vasovagal reflex 0.0281(0.0035, 0.0527) (I2 = 92.5%, P < .001), and infection 0.0027(−0.0019, 0.0073) (I2 = 49.8%, P = .113). In this systematic review and meta‐analysis, the pooled data suggested that VABB with US or mammography could be promising for diagnosis and treatment of breast disease. Further studies were necessary to identify strategies for these findings.

show abstract

“…The VABB turned out to be a low-invasive technique, well tolerated by patients, effective, and with a low rate of complications. Due to the possibility of obtaining larger tissue sections, the risk of complications in the case of VABB is slightly higher than in the case of core biopsy, mainly the risk of haematoma [ 28 ]. However, among 3804 patients who underwent VABB, only 3 patients required surgical treatment of haematoma.…”

Section: Discussionmentioning

confidence: 99%

Clinical predictors of malignancy in patients diagnosed with atypical ductal hyperplasia on vacuum-assisted core needle biopsy.

Hodorowicz-Zaniewska

Brzuszkiewicz

Szpor

et al. 2018

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

IntroductionAtypical ductal hyperplasia (ADH) is a benign lesion, which due to the risk of coexisting cancer is classified as a lesion of uncertain malignant potential.AimTo identify clinical predictors of cancer underestimation in patients with ADH diagnosed after vacuum-assisted breast biopsy (VABB).Material and methodsBetween 2001 and 2016, a total of 3804 vacuum-assisted core needle biopsies were performed at the First Chair of General Surgery of the Jagiellonian University Medical College in Krakow, including 2907 ultrasound (US)-guided biopsies and 897 digital stereotactic procedures. Seventy-six women were diagnosed with ADH and 72 of them underwent subsequent surgical excision. Demographic factors, medical history, family history, clinical symptoms, type and size of lesion determined in imaging scans, size of biopsy needle, and presence of coexisting lesions in VABB specimens were analysed as potential predictors of malignancy underestimation.ResultsUnderestimation of breast carcinoma occurred in 21 (29.2%) patients. The upgrade rate was significantly higher only in patients with a lesion visible both in mammography (MMG) and US examinations and combined BIRADS-5.ConclusionsVacuum-assisted core needle biopsy is a minimally invasive technique used in diagnosing ADH. As the risk of breast malignancy underestimation is relatively high, open surgical biopsy remains the recommended procedure, especially in patients with lesions detected both in mammography and US examination. As we could not identify the factors that preclude cancer underestimation, all the women diagnosed with ADH should be informed about the risk of cancer underestimation.

show abstract

Haematomas After Percutaneus Vacuum-Assisted Breast Biopsy

Abstract: The changes at the biopsy site can be seen by US in most of the patients one and three weeks after the VABB. These changes could potentially be used for US guidance and localisation of microcalcifications in patients requiring surgical biopsy.

Cited by 9 publications

References 7 publications

Both a biopsy method and a therapeutic procedure in BI-RADS 4A and 4B lesions: Ultrasound-guided vacuumassisted breast biopsy

Both a biopsy method and a therapeutic procedure in BI-RADS 4A and 4B lesions: Ultrasound-guided vacuumassisted breast biopsy

Feasibility and safety of image‐guided vacuum‐assisted breast biopsy: A PRISMA‐compliant systematic review and meta‐analysis of 20 000 population from 36 longitudinal studies

Clinical predictors of malignancy in patients diagnosed with atypical ductal hyperplasia on vacuum-assisted core needle biopsy.

Contact Info

Product

Resources

About